Pierre Fabre and Cordeliers Research Centre Enter into strategic partnership to identify new therapeutic targets in immuno-oncology
Castres, France, December 14, 2015 – Pierre Fabre Médicament (PFM) announces a strategic partnership with Inserm and its academic partners (Université Paris Descartes-Paris V, Université Pierre et Marie Curie-Paris VI and Université Paris Diderot-Paris VII) and Inserm Transfert to identify new therapeutic targets in immuno-oncology. Under the terms of this 3-year agreement, Cordeliers Research Center (CRC) and the Center of Immunology Pierre Fabre (CIPF) will work closely to develop tomorrow’s oncological biotherapies. Through periodic collaborative workshops, the CRC teams of Pr. Wolf-Hervé Fridman and CIPF teams will discuss their research and share their expertise in immuno-oncology. This knowledge transfer will combine CRC’s academic scientific excellence and Pierre Fabre’s know-how in the development of biomolecules and in translational medicine, as a way to select patients who might benefit the most from these new targeted treatments.
Inserm’s Cordeliers Research Centre is internationally recognized for its expertise in immuno-oncology. Pierre Fabre has extensive experience in oncology, priority for its pharmaceutical R&D.
Both partners will work closely together for the next 3 years to identify new biological targets and develop innovative therapies in immuno-oncology.
The partnership is facilitated by Inserm Transfert, Inserm’s structure dedicated to knowledge transfer.